BiotechTV

𝐁𝐢𝐨𝐕𝐞𝐧𝐭𝐮𝐫𝐞 𝐕𝐨𝐢𝐂𝐞𝐬 𝐰𝐢𝐭𝐡 𝐂𝐡𝐫𝐢𝐬 𝐆𝐚𝐫𝐚𝐛𝐞𝐝𝐢𝐚𝐧: Episode 27 | Avalon BioVentures' Jay Lichter. Full video: https://lnkd.in/gkGhgmNa Jay Lichter describes his roots growing up in Chicago, Yale, and an early career role at DuPont Merck before getting a call from Kevin Kinsella to try the world of venture at Avalon. Since that pivotal move, he describes numerous companies he either operated or funded, leading to his work today at Avalon Bioventures. BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Allucent | NYSE | Klein Hersh | Savills North America | Genezen

𝐒𝐜𝐢𝐞𝐧𝐜𝐞 𝐒𝐩𝐨𝐭𝐥𝐢𝐠𝐡𝐭: This week, Regeneron published data in NEJM showing that its gene therapy improved hearing and speech perception in 11 of 12 children with a genetic form of hearing loss. Chloe Kirk, Ph.D. breaks it down. Link to research: https://lnkd.in/gKA9mSuS BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Allucent | NYSE | Klein Hersh | Savills North America | Genezen

𝐓𝐞𝐜𝐡 + 𝐓𝐨𝐨𝐥𝐬: Emeryville, CA based Profusa is developing an injectable biosensor that aims to generate biochemistry information for users in real time. Full video: https://lnkd.in/gj2mSMRV Chairman & CEO Ben Hwang describes the idea behind Profusa's approach, and how he believes it delivers more robust and actionable information than purely surface based tools such as the Apple Watch. BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Allucent | NYSE | Klein Hersh | Savills North America | Genezen

𝐓𝐫𝐢𝐯𝐢𝐚 𝐓𝐢𝐦𝐞: What is this the chemical structure of?

𝐀𝐥𝐥𝐮𝐜𝐞𝐧𝐭: BiotechTV stopped by the Outsourcing in Clinical Trials New England Conference in Boston today and visited the booth of our sponsor, Allucent. There we caught up with Allucent's new Chief Operating Officer, Patrick Phillips BSc(Hons) D.Phil., to get his take on partnering with the right CRO. Stop by the Allucent booth today and tomorrow, or reach out anytime, to learn how Allucent leverages its expertise to help mid-and-small sized biotech companies globally.

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: PepGen's CEO James McArthur gives an overview of the company's recent data in myotonic dystrophy type 1, which showed a mean splicing correction of 53.7% at the 15 mg/kg dose. Full video: https://lnkd.in/grG2Dna7 He describes the science behind PepGen's "Enhanced Delivery Oligonucleotide (EDO)" platform, and explains how he believes it gives the company a differentiated advantage in this condition by focusing on the pathogenic repeat that causes DM1 and restoring normal function. BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Allucent | NYSE | Klein Hersh | Savills North America | Genezen

BiotechTV will be attending the Oppenheimer & Co. Inc. Miami Oncology Summit in partnership with Sylvester Comprehensive Cancer Center. Meetings with several doctors specializing in Myeloma, Radiopharma, Urinary, Prostate and NSCL/Targetable mutations.   Join us in person (institutional investors and corporates): https://lnkd.in/gNk7fHvu

𝐁𝐞𝐧𝐜𝐡𝐭𝐚𝐥𝐤 𝟐𝟎𝟐𝟓: Kate Haviland discusses the $9B+ acquisition of Blueprint by Sanofi, being chair of Fulcrum Therapeutics, her thoughts on M&A, and what is interesting in biotech today. Full interview: https://lnkd.in/gpcJCGpS The CEO of Blueprint (up to the acquisition) discusses the company's success factors, and being led to immunology by the science. Plus, why she believes an oral pill that is disease modifying, like Fulcrum is trying to develop, is strongly needed for the sickle cell patient community. BiotechTV's coverage of Benchtalk 2025 is brought to you by Benchling. BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Allucent | NYSE | Klein Hersh | Savills North America | Genezen

𝐁𝐞𝐧𝐜𝐡𝐭𝐚𝐥𝐤 𝟐𝟎𝟐𝟓: Benchling’s Head of Product - Applications Derek Halliday describes how technology is changing the ‘Development’ side of R&D, and how Benchling has helped Merck modernize its bioanalytical systems in this regard. BiotechTV’s coverage of Benchtalk 2025 is brought to you by Benchling. BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Allucent | NYSE | Klein Hersh | Savills North America | Genezen

𝐁𝐞𝐧𝐜𝐡𝐭𝐚𝐥𝐤 𝟐𝟎𝟐𝟓: Generate:Biomedicines VP of Informatics Stephen Kottmann describes the investments in technology that ensures only the highest quality data returns back into its models He walks us through the design, build, test, learn model that is the foundation of Generate's approach to drug development. Full video: https://lnkd.in/gMMRVEcY BiotechTV's coverage of Benchtalk 2025 is brought to you by Benchling. BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Allucent | NYSE | Klein Hersh | Savills North America | Genezen